Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Colon Cancer Molecular and Targeted Experimental Therapy

  • Yun Dai
  • George Wilson
  • Liang Qiao
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_6589-3


Colorectal cancer (CRC) is the third most common cancer and the third leading cause of cancer death in the USA. CRC incidence rates have rapidly increased in several regions where the incidence was historically low, including parts of East Asia and Eastern Europe. In 2014, it was estimated that 136,830 new cases and 50,310 deaths have occurred in the USA and over 1.2 million new cases and some 600,000 deaths have occurred worldwide. The prognosis of CRC declines rapidly with the advanced staging. According to the American Joint Committee on Cancer (AJCC) staging system, the overall 5-year survival of patients with stage I CRC was greater than 90 %, whereas that of the stage IV was less than 10 %. Unfortunately, surgical resection is not suitable for the vast majority of CRC patients who have metastatic disease. As a result, more effective treatment approaches for CRC are needed.


Molecularly Targeted Therapies

Advances in the understanding of cellular and...


Vascular Endothelial Growth Factor Hepatocyte Growth Factor mCRC Patient Adoptive Cell Therapy Extrinsic Apoptosis Pathway 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.



This work was partially supported by the Robert W. Storr Bequest to the Sydney Medical Foundation, University of Sydney, a National Health and Medical Research Council of Australia (NHMRC) Project grant to LQ (ID: APP1047417), and two Cancer Council NSW grants to LQ (ID: APP1070076) and LH (ID: APP1069733).


  1. Camidge DR, Herbst RS, Gordon MS, Eckhardt SG, Kurzrock R, Durbin B, Ing J, Tohnya TM, Sager J, Ashkenazi A, Bray G, Mendelson D (2010) A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clin Cancer Res 16(4):1256–1263CrossRefPubMedGoogle Scholar
  2. Correale P, Botta C, Rotundo MS, Guglielmo A, Conca R, Licchetta A, Pastina P, Bestoso E, Ciliberto D, Cusi MG, Fioravanti A, Guidelli GM, Bianco MT, Misso G, Martino E, Caraglia M, Tassone P, Mini E, Mantovani G, Ridolfi R, Pirtoli L, Tagliaferri P (2014) Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. J Immunother 37(1):26–35CrossRefPubMedGoogle Scholar
  3. de Sousa EM, Vermeulen L, Richel D, Medema JP (2011) Targeting Wnt signaling in colon cancer stem cells. Clin Cancer Res 17(4):647–653CrossRefPubMedGoogle Scholar
  4. Holt SV, Logie A, Davies BR, Alferez D, Runswick S, Fenton S, Chresta CM, Gu Y, Zhang J, Wu YL, Wilkinson RW, Guichard SM, Smith PD (2012) Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res 72(7):1804–1813CrossRefPubMedGoogle Scholar
  5. Kemper K, Grandela C, Medema JP (2010) Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 1(6):387–395PubMedCentralCrossRefPubMedGoogle Scholar
  6. Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA, Xu H, Yao S, Pons A, Chen L, Pardoll DM, Brahmer JR, Topalian SL (2013) Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 19(2):462–468PubMedCentralCrossRefPubMedGoogle Scholar
  7. Martinelli E, Troiani T, Morgillo F, Orditura M, De Vita F, Belli G, Ciardiello F (2013) Emerging VEGF-receptor inhibitors for colorectal cancer. Expert Opin Emerg Drugs 18(1):25–37CrossRefPubMedGoogle Scholar
  8. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, Thatcher N, Wagstaff J, Zielinski C, Faulkner I, Mellstedt H (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 11(9):509–524CrossRefPubMedGoogle Scholar
  9. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18(8):2316–2325CrossRefPubMedGoogle Scholar
  10. Smyth EC, Sclafani F, Cunningham D (2014) Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 12(7):1001–1014CrossRefGoogle Scholar
  11. Tang PA, Cohen SJ, Kollmannsberger C, Bjarnason G, Virik K, MacKenzie MJ, Lourenco L, Wang L, Chen A, Moore MJ (2012) Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer. Clin Cancer Res 18(21):6023–6031CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of GastroenterologyPeking University First HospitalBeijingChina
  2. 2.Storr Liver Centre, Westmead Millennium Institute for Medical ResearchUniversity of Sydney at Westmead HospitalWestmeadAustralia